A carregar...
Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system
Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA‐approved drug rapamycin has been shown to promote lifespan and delay age‐related diseases in model organisms including mice. Unfortunately, rapamycin has potentially serious side effects in humans, including glucos...
Na minha lista:
| Publicado no: | Aging Cell |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4717280/ https://ncbi.nlm.nih.gov/pubmed/26463117 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acel.12405 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|